Iovance Biotherapeutics Inc at Truist Securities Life Sciences Summit (May Series) Transcript
Hello, everyone, and welcome to our next session. My name is Asthika Goonewardene. We are thrilled to have the folks from Iovance with us on this installment of the Truist Securities Life Sciences Summit.
From the company, we have Maria Fardis, President and CEO, joining us today. Maria, welcome. It's a pleasure to have you here, first time on our platform.
Thank you for the invite. Much appreciate the initiation of the coverage as well.
Yes. I might as well mention that. So we actually just freshly initiated coverage on Iovance with a buy just on Monday. We are definitely just about the deal space, and we'll talk about that more. Before we start, let me read out my disclosure, and I'm going to hand over to Maria to do some introductions to the company.
So this call is arranged by Truist Securities Research for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |